Skip To Main Content
Yin-Ling Chan on Muck Rack

Yin-Ling Chan

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yin-Ling

Contact Yin-Ling, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial

|
By Ana C. Veneziani, Stephanie Lheureux, Douglas G. Millar, Neesha Dhani, Ilaria Colombo, Ainhoa Madariaga, Pamela Piña, Joshua Lee, Lisa Wang, Xuan Li, Ben Wang, Amit M Oza, Swati Atale, Yin-Ling Chan, Janelle Ramsahai, Judy Quintos, Valerie Bowering, Pam Ohashi
| Nature Verified
Abstract This investigator-initiated, open-label phase 1/2 clinical trial evaluates maveropepimut-S, a survivin-targeting vaccine, combined with pembrolizumab and low-dose cyclophosphamide in patients with recurrent epithelial ovarian cancer (ClinicalTrials.gov identifier: NCT03029403). The primary endpoints are safety and clinical efficacy measured by overall response rate and disease control rate.
Open in Who Shared Issue with article?
See all 1 articles